Rice Hall James & Associates LLC increased its stake in shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 24.3% during the second quarter, Holdings Channel reports. The firm owned 1,364,879 shares of the biotechnology company’s stock after buying an additional 266,763 shares during the period. Rice Hall James & Associates LLC’s holdings in Progenics Pharmaceuticals were worth $9,268,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Teachers Advisors LLC boosted its stake in shares of Progenics Pharmaceuticals by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 111,935 shares of the biotechnology company’s stock valued at $967,000 after buying an additional 2,769 shares during the period. Capstone Asset Management Co. bought a new stake in shares of Progenics Pharmaceuticals during the first quarter valued at about $392,000. Fox Run Management L.L.C. boosted its stake in shares of Progenics Pharmaceuticals by 64.1% in the first quarter. Fox Run Management L.L.C. now owns 19,532 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 7,632 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of Progenics Pharmaceuticals during the first quarter valued at about $269,000. Finally, Fisher Asset Management LLC boosted its stake in shares of Progenics Pharmaceuticals by 23.5% in the first quarter. Fisher Asset Management LLC now owns 97,632 shares of the biotechnology company’s stock valued at $922,000 after buying an additional 18,604 shares during the period. 92.20% of the stock is currently owned by institutional investors and hedge funds.

Shares of Progenics Pharmaceuticals Inc. (PGNX) opened at 5.63 on Friday. The firm’s 50-day moving average price is $6.49 and its 200 day moving average price is $8.17. Progenics Pharmaceuticals Inc. has a 12 month low of $4.60 and a 12 month high of $11.72. The company’s market cap is $395.24 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.04. Progenics Pharmaceuticals had a negative return on equity of 4.11% and a negative net margin of 6.13%. The company had revenue of $2.77 million for the quarter, compared to analysts’ expectations of $3.34 million. During the same period in the prior year, the company posted ($0.08) EPS. The firm’s revenue was down 67.3% compared to the same quarter last year. Equities research analysts anticipate that Progenics Pharmaceuticals Inc. will post ($0.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/13/rice-hall-james-associates-llc-buys-266763-shares-of-progenics-pharmaceuticals-inc-nasdaqpgnx.html.

Several analysts have issued reports on PGNX shares. Needham & Company LLC reaffirmed a “strong-buy” rating on shares of Progenics Pharmaceuticals in a research report on Monday, April 24th. Zacks Investment Research cut Progenics Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Wednesday, May 10th. TheStreet cut Progenics Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $12.00 target price on shares of Progenics Pharmaceuticals in a research report on Thursday, June 8th. Finally, BidaskClub cut Progenics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $12.33.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.